12/18
08:07 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, up previously from $11.00.
Low
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, up previously from $11.00.
12/16
04:01 pm
cadl
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Medium
Report
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
12/12
11:00 pm
cadl
Candel Therapeutics Announces Pricing of Public Offering
Medium
Report
Candel Therapeutics Announces Pricing of Public Offering
12/12
04:51 pm
cadl
Candel Therapeutics Announces $80 Million Proposed Public Offering
High
Report
Candel Therapeutics Announces $80 Million Proposed Public Offering
12/11
10:51 am
cadl
Candel Therapeutics stock up 172% after Phase III prostate cancer success [Yahoo! Finance]
Low
Report
Candel Therapeutics stock up 172% after Phase III prostate cancer success [Yahoo! Finance]
12/11
09:41 am
cadl
Market movers: Stocks seeing action on Wednesday - and why [Globe and Mail, The (Toronto, Canada)]
High
Report
Market movers: Stocks seeing action on Wednesday - and why [Globe and Mail, The (Toronto, Canada)]
12/11
09:30 am
cadl
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug [Yahoo! Finance]
High
Report
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug [Yahoo! Finance]
12/11
07:10 am
cadl
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival [Yahoo! Finance]
High
Report
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival [Yahoo! Finance]
12/11
07:00 am
cadl
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
High
Report
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
11/18
08:07 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
11/18
05:33 am
cadl
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
11/14
03:34 pm
cadl
Candel Therapeutics reports Q3 results [Seeking Alpha]
Low
Report
Candel Therapeutics reports Q3 results [Seeking Alpha]
11/14
08:12 am
cadl
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Low
Report
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
11/14
08:00 am
cadl
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Low
Report
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
11/7
08:00 am
cadl
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
Medium
Report
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
11/5
09:00 am
cadl
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Medium
Report
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
10/28
08:00 am
cadl
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Low
Report
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
10/4
09:00 am
cadl
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Neutral
Report
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting